This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Sanofi sees UPC agree to post-merger substitution in patent dispute

( January 8, 2025, 09:29 GMT | Official Statement) -- MLex Summary: The Unified Patent Court's Local Division in Munich accepted Sanofi's request for substitution in the patent infringement proceeding, allowing Sanofi Winthrop Industrie to replace Sanofi-Aventis France as the claimant. The dispute concerns European Patent 2,493,466, with defendants including Accord Healthcare, STADA, Reddy Pharma, and Zentiva. The defendants argued that the substitution should not be allowed post-merger, citing a lack of standing. However, the Court ruled in favor of Sanofi, acknowledging the legal transfer of rights and obligations due to the merger.The decision is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections